Artiva Biotherapeutics (ARTV) Equity Average (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Equity Average data on file, last reported at $98.9 million in Q1 2026.

• Equity Average for Q1 2026 came in at $98.9 million, down 44.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $98.9 million (down 44.34% YoY), and the FY2025 annual result was $148.3 million, up 1104.46% from the prior year.
• Equity Average retreated to $98.9 million in Q1 2026 per ARTV's latest filing, from $119.6 million in the prior quarter.
• Over five years, Equity Average peaked at $193.8 million in Q4 2024 and troughed at -$182.9 million in Q2 2024.
• A 4-year average of $20.7 million and a median of $98.9 million in 2026 frame the typical range for Equity Average.
• The sharpest annual moves came in 2025 and 2026: Equity Average surged 2711.04% in 2025, then tumbled 44.34% in 2026.
• A 4-year view of Equity Average shows it stood at -$156.7 million in 2023, then jumped by 223.66% to $193.8 million in 2024, then slumped by 38.29% to $119.6 million in 2025, then slipped by 17.3% to $98.9 million in 2026.
• Business Quant data shows ARTV's Equity Average at $98.9 million in Q1 2026, $119.6 million in Q4 2025, and $139.1 million in Q3 2025.